We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Research Could Lower Malfunction Rates for Medical Implants

By HospiMedica International staff writers
Posted on 15 Mar 2023

Medical implants can save lives or significantly improve quality of life, but they can also trigger an immune response in our bodies. More...

When immune cells respond to these foreign objects, it can lead to the accumulation of excess tissue at the site - this is known as fibrosis or scarring. Traditionally, protein deposition has been linked to the fibrotic response to implants. Now, bioengineers at Rice University (Houston, TX, USA) have discovered that lipids on the surfaces of implants can also play a role in mediating the body's response. Some lipids may act as "peacekeepers" while others may cause conflict.

With this knowledge, scientists could develop biomaterials or coatings for implants that reduce the aggressive response from the host immune system. This would decrease the malfunction rates for numerous biomedical devices including pacemakers, coronary stents, surgical meshes, drug delivery pumps, and biosensors. The researchers believe that optimizing implant performance is particularly important for patients with chronic and life-threatening conditions like hydrocephalus, where excess cerebrospinal fluid in the brain can only be managed by placing a CSF shunt. Pediatric hydrocephalus patients face especially high rates of implant failure, which can lead to severe consequences such as brain injury, loss of vision, headaches, vomiting, and even death if not addressed promptly.

“In our research, we realized that, while proteins are important, fat molecules also play a significant role in the fibrotic process,” said Christian Schreib is a Rice graduate student and lead author on the study. “We identified two lipid profiles, fatty acids and phospholipids. Fatty acids are more likely to provoke an immune response, while phospholipids are more likely to fly under the radar and not irk the immune system.”

“Now that we understand this, we can use this knowledge to engineer materials for use in implants that are less likely to trigger an immune response. We could, say, engineer a material that pulls in phospholipids to it, so that when you implant the material, the phospholipids naturally deposit onto it and help it evade the immune system. We might also want to look at taking those fat molecules like the phospholipids and chemically functionalize them to the device surface before implantation,” added Schreib.

Related Links:
Rice University 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.